IBDEI1AO ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,22932,2)
 ;;=HIV Disease (symptomatic)^266500
 ;;^UTILITY(U,$J,358.3,22933,0)
 ;;=464.00^^125^1398^2
 ;;^UTILITY(U,$J,358.3,22933,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22933,1,4,0)
 ;;=4^464.00
 ;;^UTILITY(U,$J,358.3,22933,1,5,0)
 ;;=5^Acute Laryngitis
 ;;^UTILITY(U,$J,358.3,22933,2)
 ;;=Acute Laryngitis^323469
 ;;^UTILITY(U,$J,358.3,22934,0)
 ;;=790.6^^125^1398^1
 ;;^UTILITY(U,$J,358.3,22934,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22934,1,4,0)
 ;;=4^790.6
 ;;^UTILITY(U,$J,358.3,22934,1,5,0)
 ;;=5^Abnormal LFT's
 ;;^UTILITY(U,$J,358.3,22934,2)
 ;;=^87228
 ;;^UTILITY(U,$J,358.3,22935,0)
 ;;=780.60^^125^1398^20
 ;;^UTILITY(U,$J,358.3,22935,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22935,1,4,0)
 ;;=4^780.60
 ;;^UTILITY(U,$J,358.3,22935,1,5,0)
 ;;=5^Fever
 ;;^UTILITY(U,$J,358.3,22935,2)
 ;;=^336764
 ;;^UTILITY(U,$J,358.3,22936,0)
 ;;=795.51^^125^1398^55
 ;;^UTILITY(U,$J,358.3,22936,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22936,1,4,0)
 ;;=4^795.51
 ;;^UTILITY(U,$J,358.3,22936,1,5,0)
 ;;=5^Pos PPD w/o Active TB
 ;;^UTILITY(U,$J,358.3,22936,2)
 ;;=^340572
 ;;^UTILITY(U,$J,358.3,22937,0)
 ;;=482.9^^125^1398^53
 ;;^UTILITY(U,$J,358.3,22937,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22937,1,4,0)
 ;;=4^482.9
 ;;^UTILITY(U,$J,358.3,22937,1,5,0)
 ;;=5^Pneumonia,Bacterial
 ;;^UTILITY(U,$J,358.3,22937,2)
 ;;=^12347
 ;;^UTILITY(U,$J,358.3,22938,0)
 ;;=571.42^^125^1398^31
 ;;^UTILITY(U,$J,358.3,22938,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22938,1,4,0)
 ;;=4^571.42
 ;;^UTILITY(U,$J,358.3,22938,1,5,0)
 ;;=5^Hepatitis, Autoimunne
 ;;^UTILITY(U,$J,358.3,22938,2)
 ;;=^336610
 ;;^UTILITY(U,$J,358.3,22939,0)
 ;;=795.52^^125^1398^54
 ;;^UTILITY(U,$J,358.3,22939,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22939,1,4,0)
 ;;=4^795.52
 ;;^UTILITY(U,$J,358.3,22939,1,5,0)
 ;;=5^Pos GMA Interferon w/o Active TB
 ;;^UTILITY(U,$J,358.3,22939,2)
 ;;=^340573
 ;;^UTILITY(U,$J,358.3,22940,0)
 ;;=682.0^^125^1399^6
 ;;^UTILITY(U,$J,358.3,22940,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22940,1,4,0)
 ;;=4^682.0
 ;;^UTILITY(U,$J,358.3,22940,1,5,0)
 ;;=5^Cellulitis Of Face
 ;;^UTILITY(U,$J,358.3,22940,2)
 ;;=^271888
 ;;^UTILITY(U,$J,358.3,22941,0)
 ;;=681.00^^125^1399^7
 ;;^UTILITY(U,$J,358.3,22941,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22941,1,4,0)
 ;;=4^681.00
 ;;^UTILITY(U,$J,358.3,22941,1,5,0)
 ;;=5^Cellulitis Of Finger NOS
 ;;^UTILITY(U,$J,358.3,22941,2)
 ;;=^271883
 ;;^UTILITY(U,$J,358.3,22942,0)
 ;;=682.7^^125^1399^8
 ;;^UTILITY(U,$J,358.3,22942,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22942,1,4,0)
 ;;=4^682.7
 ;;^UTILITY(U,$J,358.3,22942,1,5,0)
 ;;=5^Cellulitis Of Foot
 ;;^UTILITY(U,$J,358.3,22942,2)
 ;;=^271895
 ;;^UTILITY(U,$J,358.3,22943,0)
 ;;=682.4^^125^1399^9
 ;;^UTILITY(U,$J,358.3,22943,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22943,1,4,0)
 ;;=4^682.4
 ;;^UTILITY(U,$J,358.3,22943,1,5,0)
 ;;=5^Cellulitis Of Hand
 ;;^UTILITY(U,$J,358.3,22943,2)
 ;;=^271892
 ;;^UTILITY(U,$J,358.3,22944,0)
 ;;=682.6^^125^1399^10
 ;;^UTILITY(U,$J,358.3,22944,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22944,1,4,0)
 ;;=4^682.6
 ;;^UTILITY(U,$J,358.3,22944,1,5,0)
 ;;=5^Cellulitis Of Leg
 ;;^UTILITY(U,$J,358.3,22944,2)
 ;;=^271894
 ;;^UTILITY(U,$J,358.3,22945,0)
 ;;=682.1^^125^1399^11
 ;;^UTILITY(U,$J,358.3,22945,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22945,1,4,0)
 ;;=4^682.1
 ;;^UTILITY(U,$J,358.3,22945,1,5,0)
 ;;=5^Cellulitis Of Neck
 ;;^UTILITY(U,$J,358.3,22945,2)
 ;;=^271889
 ;;^UTILITY(U,$J,358.3,22946,0)
 ;;=376.01^^125^1399^12
 ;;^UTILITY(U,$J,358.3,22946,1,0)
 ;;=^358.31IA^5^2
 ;;
 ;;$END ROU IBDEI1AO
